Prostate Cancer Daily

November 18, 2024

Videos

Peer-to-Peer Clinical Conversations

INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra

Niven Mehra

Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial.

Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl

Ursula Vogl

Ursula Vogl discusses key prostate cancer highlights from ESMO 2024.

Beyond the Abstracts

First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract

Preclinical and Clinical Evidence for Using Perinatal Tissue Allografts in Nerve Sparing Robot Assisted Radical Prostatectomy to Hasten Recovery of Functional Outcomes: A Literature Review - Beyond the Abstract

Conference Coverage

SCS AUA 2024: Should Veterans be Classified as High Risk for Prostate Cancer Screening: A Review of the Current Literature

ASTRO 2024: Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP)

ASTRO 2024: Precision in Practice: Optimizing Prostate Radiation with MRI-Defined Microboost

ASTRO 2024: Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients with Localized Prostate Cancer: Toxicity and Quality-of Life Results from a Prospective Trial

ESMO 2024: HARMONY: A Phase II Study of Niraparib/Abiraterone Acetate plus Prednisone for Hispanic/Latinoand Non-Hispanic Black Patients with Metastatic Hormone Sensitive Prostate Cancer and Deleterious Homologous Recombination Repair Alterations

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.

Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings.

Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries.

HSD3B1, prostate cancer mortality and modifiable outcomes.

Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC